Racivir
Clinical data | |
---|---|
Routes of administration | Investigational |
ATC code |
|
Identifiers | |
| |
JSmol) | |
| |
|
Racivir is an experimental
nucleoside reverse transcriptase inhibitor (NRTI), developed by Pharmasset for the treatment of HIV.[1] It is the enantiomer of emtricitabine, a widely used NRTI, meaning that the two compounds are mirror images
of each other.
References
- ^ "Racivir". AIDSmeds.com. March 24, 2006. Archived from the original on 2014-01-02. Retrieved March 21, 2008.